Table 1. Clinical outcomes of TKIs on IM/SU-resistant GIST.

Administration	Studies	N	SD>6 months	PFS (months)	OS (months)
Best supportive care	Italiano [26]	18	11%	2.1	2.4
Nilotinib	Italiano [26]	67	35%	4.1	11.8
	Cauchi [31]	13	7%	2.0	N.A.
	Montemurro [29]	52	47%	3	8.5
	Kim [30]	17	47%	5.9	18.5
	Sawaki [25]	35	29%	3.8	10.3
Sorafenib	Italiano [26]	55	42%	4.9	10.7
	Park [27]	31	36%	4.9	9.7
	Kindler [28]	32	32%	5.2	11.6
Dasatinib	Trent [32]	47	21%	3.8	10.3

S.D.: stable disease; PFS: progression-free survival; OS: overall survival; N.A: not available.